Chardan Capital Reiterates Buy on Opus Genetics, Sets $16 Target
Chardan Capital maintained its Buy rating on Opus Genetics, setting a price target of $16.00. This target represents a potential upside of 254.8% from the stock's previous closing price of $4.51.